Search

Ruthenium(III), gold(III), and iridium(III) trimethoprim drug (TMP) complexes were synthesized and analyses via microanalytical approach (C, H, N analysis), magnetic, molar conductance, and FTIR, 1H NMR, XRD, and UV-Vis spectroscopy. Through two nitrogen atoms of --NH2 amino groups, the TMP drug coordinated as a bidentate ligand towards the corresponding three metal ions. The geometrical structure of the compounds ruthenium(III), gold(III), and iridium(III) is octahedral and consists of two TMP molecules, two coordinated chlorine atoms, and one uncoordinated chlorine atom. The antibacterial properties of TMP complexes have been investigated through the use of many bacterial species, including Pseudomonas aeruginosa, Bacillus subtilis, Staphylococcus aureus, and Escherichia coli. Additionally, the generated complexes' anticancer properties against HepG-2 (human hepatocellular carcinoma) and MCF-7 (human breast cancer cell line) have been assessed. In contrast to those of clinically used antibiotics, the inhibition zone of ruthenium and iridium(III) complexes was in the low efficiency range, and the antibacterial activity of gold(III) complexes was moderate. This article discusses the possibilities and prospects for this family of metallodrugs as antibacterial or anticancer medicines. [ABSTRACT FROM AUTHOR]

The aim of this study was to investigate the antibacterial activity, antibiotic-associated synergy, and anti-biofilm activity of the ruthenium complex, cis-[RuCl2 (dppb) (bqdi)]2+ (RuNN). RuNN exhibited antimicrobial activity against Gram-positive bacteria with minimum inhibitory concentration (MIC) values ranging from 15.6 to 62.5 µg ml−1 and minimum bactericidal concentration (MBC) values ranging from 62.5 to 125 µg ml−1. A synergistic effect against Staphylococcus spp. was observed when RuNN was combined with ampicillin, and the range of associated fractional inhibitory concentration index (FICI) values was 0.187 to 0.312. A time-kill curve indicated the bactericidal activity of RuNN in the first 1–5 h. In general, RuNN inhibited biofilm formation and disrupted mature biofilms. Furthermore, RuNN altered the cellular morphology of S. aureus biofilms. Further, RuNN did not cause hemolysis of erythrocytes. The results of this study provide evidence that RuNN is a novel therapeutic candidate to treat bacterial infections caused by Staphylococcus biofilms. [ABSTRACT FROM AUTHOR]

The widespread use of antibiotics has resulted in the emergence of drug-resistant populations of microorganisms. Clearly, one can see the need to develop new, more effective, antimicrobial agents that go beyond the explored 'chemical space'. In this regard, their unique modes of action (e.g., reactive oxygen species (ROS) generation, redox activation, ligand exchange, depletion of substrates involved in vital cellular processes) render metal complexes as promising drug candidates. Several Ru (II/III) complexes have been included in, or are currently undergoing, clinical trials as anticancer agents. Based on the in-depth knowledge of their chemical properties and biological behavior, the interest in developing new ruthenium compounds as antibiotic, antifungal, antiparasitic, or antiviral drugs has risen. This review will discuss the advantages and disadvantages of Ru (II/III) frameworks as antimicrobial agents. Some aspects regarding the relationship between their chemical structure and mechanism of action, cellular localization, and/or metabolism of the ruthenium complexes in bacterial and eukaryotic cells are discussed as well. Regarding the antiviral activity, in light of current events related to the Covid-19 pandemic, the Ru (II/III) compounds used against SARS-CoV-2 (e.g., BOLD-100) are also reviewed herein. [ABSTRACT FROM AUTHOR]